Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease: The Randomized Controlled Lp(a)FRONTIERS EXPANSION Study
Primary result · Change in log-transformed Lp(a) from baseline (GMR of Lp(a) to baseline)Result — go to the resultGeometric mean ratio 0.14 95% CI 0.11–0.18Authors' conclusion
This study is the first to demonstrate robust Lp(a) lowering with pelacarsen, which was generally well tolerated, in US Black/African American and Hispanic participants, populations disproportionately impacted by Lp(a)-associated CV risk.
Study context
- Population
- US Black/African American and Hispanic adults with elevated Lp(a) (≥125 nmol/L) and atherosclerotic cardiovascular disease (ASCVD)analyzed, 423 randomized · 272 (Black/non-Hispanic) · 127 (nonBlack/Hispanic) · 23 (Black/Hispanic)
- Participants
- 422 participants
- Comparison
- Pelacarsen vs placebo
- Pelacarsenn = 282
- Placebon = 140
- Primary endpoint
- Change in log-transformed Lp(a) from baseline (GMR of Lp(a) to baseline)
- Follow-up
- Week 52
Primary result
As reported in the abstract
Change in log-transformed Lp(a) from baseline (GMR of Lp(a) to baseline)
Geometric mean ratio
0.14
95% CI 0.11–0.18
P < 0.0001
Change by group
Pelacarsen
0.14
Geometric mean ratio (GMR) to baseline · 95% CI 0.12–0.16
Placebo
0.98
GMR to baseline · 95% CI 0.80–1.20
Pelacarsenvs placebo
GMR 0.14 (95% CI 0.11–0.18); P < 0.0001
Further findings
Trial completion
Safety
TEAEs
Serious TEAEs
TEAE-related treatment discontinuations
Original publication
Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease: The Randomized Controlled Lp(a)FRONTIERS EXPANSION Study. Circ Popul Health Outcomes. Published 9 November 2026. doi:10. 1161/ circoutcomes. 126. 014453
Composed by AI from the published abstract and checked against it. How Briefs are made →